PD-1/PD-L1
Les inhibiteurs de PD-1/PD-L1 sont des inhibiteurs de points de contrôle immunitaires qui bloquent l'interaction entre la protéine de mort cellulaire programmée 1 (PD-1) sur les cellules T et son ligand PD-L1 sur les cellules cancéreuses. Cette interaction supprime normalement la réponse immunitaire et permet aux cellules cancéreuses d'échapper à la détection immunitaire. En inhibant PD-1/PD-L1, ces inhibiteurs renforcent la capacité du système immunitaire à reconnaître et à détruire les cellules cancéreuses, induisant l'apoptose et la régression tumorale. Les inhibiteurs de PD-1/PD-L1 sont essentiels dans la recherche en immunothérapie et dans le traitement du cancer. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de PD-1/PD-L1 de haute qualité pour soutenir vos recherches en immuno-oncologie, apoptose et thérapie contre le cancer.
140 produits trouvés pour "PD-1/PD-L1"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BMS-1001 hydrochloride
CAS :BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormule :C35H35ClN2O7Degré de pureté :97.36%Couleur et forme :SolidMasse moléculaire :631.11Ref: TM-T10565
1mg52,00€5mg120,00€1mL*10mM (DMSO)169,00€10mg187,00€25mg380,00€50mg612,00€100mg973,00€200mg1.305,00€Budigalimab
CAS :Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Degré de pureté :97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :145.72 kDaSpartalizumab
CAS :"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Degré de pureté :SDS-PAGE:95.2%;SEC-HPLC:96.3%Couleur et forme :LiquidMasse moléculaire :145.74 kDaTislelizumab
CAS :Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Degré de pureté :95.07%Couleur et forme :LiquidMasse moléculaire :145 kDaEzabenlimab
CAS :Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Degré de pureté :99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :145.21 kDaPenpulimab
CAS :Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Degré de pureté :96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :145.14 kDaAUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormule :C144H230N40O50Degré de pureté :95.07%Couleur et forme :SolidMasse moléculaire :3321.61Sintilimab
CAS :Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Degré de pureté :> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :143.78 kDaZimberelimab
CAS :Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Degré de pureté :95%Couleur et forme :LiquidMasse moléculaire :146.54 kDaDostarlimab
CAS :Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Degré de pureté :>95%Couleur et forme :LiquidMasse moléculaire :144.18 kDaDurvalumab
CAS :Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Degré de pureté :95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :146.03 kDaOpamtistomig
CAS :Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.Couleur et forme :LiquidPMT-O9-1A
PMT-O9-1A is an effective PD-L1 degrader that reduces PD-L1 protein expression and exhibits cytotoxic properties. Additionally, PMT-O9-1A possesses anticancer activity.Formule :C22H25ClN2O4Couleur et forme :SolidMasse moléculaire :416.90Human membrane-bound PD-L1 polypeptide
CAS :Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].Formule :C85H140N26O36SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :2134.24Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.Couleur et forme :Odour LiquidGJ19
GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. It binds effectively to human and mouse PD-L1 proteins, exhibiting KD values of 171 nM and 290 nM, respectively. In a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells, GJ19 promotes HepG2 cell death in a concentration-dependent manner. In the B16-F10 melanoma mouse model, GJ19 demonstrates significant tumor growth inhibition. GJ19 is applicable in tumor immunotherapy research.Couleur et forme :Odour SolidAnti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
Anti-MousePD-1Antibody (D265A) is an antibody inhibitor targeting the PD-1 protein in mice.Couleur et forme :Odour LiquidIparomlimab
CAS :Iparomlimab: anti-PD-1 IgG4κ antibody, targets PSB103 γ4/κ-chains, forms dimers, used in cancer research.Couleur et forme :LiquidRTX-002
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. This compound is applicable in the research of autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.Couleur et forme :Odour LiquidAM0001
AM0001 is a human monoclonal antibody (mAb) that targets PDCD1/PD-1/CD279. It is applicable in cancer research.Couleur et forme :Odour LiquidGR-1405
GR-1405 is a human monoclonal antibody (mAb) that targets B7-H1/PD-L1/CD274. It enhances the antitumor immune response mediated by cytotoxic T lymphocytes (CTL) against tumor cells expressing PD-L1. GR-1405 is applicable in research related to lymphomas and solid tumors.Couleur et forme :Odour LiquidPD-1/PD-L1-IN-40
PD-1/PD-L1-IN-40 (Compound EP16) is a PD-1/PD-L1 inhibitor. It effectively suppresses the production of exosomal PD-L1 with an IC50 of 0.108 μM. PD-1/PD-L1-IN-40 serves as a lead compound for the elimination of exosomal PD-L1 and is applicable in cancer research.Formule :C20H22N4O2Masse moléculaire :350.17428PD-1/PD-L1-IN-9
CAS :PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formule :C22H24N2O2Degré de pureté :99.92%Couleur et forme :SolidMasse moléculaire :348.44Ref: TM-T9651
1mg57,00€2mg85,00€5mg127,00€1mL*10mM (DMSO)140,00€10mg178,00€25mg298,00€50mg405,00€100mg535,00€500mg1.063,00€PD-1/PD-L1-IN-50
Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.Couleur et forme :Odour SolidPD-1/PD-L1-IN-48
PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.Couleur et forme :Odour SolidHuman PD-L1 inhibitor I
CAS :Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formule :C110H152N26O32Couleur et forme :SolidMasse moléculaire :2350.576BMSpep-57
CAS :BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.Formule :C89H126N24O19SCouleur et forme :SolidMasse moléculaire :1868.2Human PD-L1 inhibitor II
CAS :Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Formule :C103H151N25O30Couleur et forme :SolidMasse moléculaire :2219.486TQB-2858
TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).Couleur et forme :Odour LiquidPD-1/PD-L1-IN-51
PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.Couleur et forme :Odour SolidBAT-1306
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. It is applicable for research in colorectal cancer and solid tumors.Couleur et forme :Odour LiquidPD-1/PD-L1 inhibitory peptide C8
PD-1/PD-L1 inhibitory peptide C8 disrupts the PD-1/PD-L1 interaction, leading to the activation of CD8+ and CD4+ T cells and an increase in IFN-γ secretion. In mouse models, PD-1/PD-L1 inhibitory peptide C8 has demonstrated antitumor activity.Formule :C51H72N14O14S2Couleur et forme :SolidMasse moléculaire :1169.33PROTAC PD-1/PD-L1 degrader-1
CAS :PROTAC PD-1/PD-L1 degrader-1, a Cereblon-based inhibitor, blocks PD-1/PD-L1 with 39.2 nM IC50, boosting immune response and reducing PD-L1 via lysosomes.Formule :C59H58ClN7O11Degré de pureté :99.07%Couleur et forme :SolidMasse moléculaire :1076.59PROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.H-20
CAS :H-20 is a PD-1 agonist that reduces the required dosage of morphine for analgesia. It can be used in studies related to chronic pain.Formule :C44H64N10O15Couleur et forme :SolidMasse moléculaire :973.037PD-1/PD-L1-IN-39
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.Formule :C23H20ClFN2O3Masse moléculaire :426.11465PD-L1-IN-5
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.OPBP-1
OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.Formule :C64H92N20O19SMasse moléculaire :1476.65683PD-L1/VISTA-IN-2
PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.Formule :C22H22N2O3Couleur et forme :SolidMasse moléculaire :362.42PD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Couleur et forme :Odour SolidCamrelizumab
CAS :Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up
Degré de pureté :95% - 98.6%Couleur et forme :LiquidMasse moléculaire :143.7 kDaSotiburafusp alfa
CAS :Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedDegré de pureté :98%Couleur et forme :SolidPacmilimab
CAS :Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.Degré de pureté :98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :153.3 kDaEciskafusp alfa
CAS :Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificDegré de pureté :98%Couleur et forme :SolidProlgolimab
CAS :Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.Degré de pureté :>95%Couleur et forme :LiquidMasse moléculaire :146.28 kDaAsudemotide
CAS :Asudemotide is a bioactive chemical.Formule :C58H80N10O17Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1189.31Human PD-L1 inhibitor III
CAS :Human PD-L1 inhibitor III is a human PD-L1 inhibitor.Formule :C97H155N29O29SCouleur et forme :SolidMasse moléculaire :2223.54AUNP-12
CAS :AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.Formule :C142H226N40O48Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :3261.55TPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formule :C109H151F3N34O34S2Couleur et forme :SolidMasse moléculaire :2602.69Human PD-L1 inhibitor IV
CAS :PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.Formule :C80H113N25O27Couleur et forme :SolidMasse moléculaire :1856.932
